Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
The DOI matches its Crossref record; 28 of the 31 references it cites were found in a registry or an index.
Abstract
Apoptosis is a genetically encoded programme of cell death that can be activated under physiological conditions and may be an important safeguard against tumour development. Regions of low oxygen (hypoxia) and necrosis are common features of solid tumours. Here we report that hypoxia induces apoptosis in oncogenically transformed cells and that further genetic alterations, such as loss of the p53 tumour-suppressor gene or overexpression of the apoptosis-inhibitor protein Bcl-2, substantially reduce hypoxia-induced cell death. Hypoxia also selects for cells with defects in apoptosis, because small numbers of transformed cells lacking p53 overtake similar cells expressing wild-type p53 when treated with hypoxia. Furthermore, highly apoptotic regions strongly correlate with hypoxic regions in transplanted tumours expressing wild-type p53, whereas little apoptosis occurs in hypoxic regions of p53-deficient tumours. We propose that hypoxia provides a physiological selective pressure in tumours for the expansion of variants that have lost their apoptotic potential, and in particular for cells acquiring p53 mutations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Giaccia and co-workers demonstrated that hypoxia can induce tumor cell apoptosis, an effect that was reduced by loss of p53 tumor suppressor function or overexpression of anti-apoptotic Bcl-2 (Graeber et al., 1996).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Graeber et al., 1996
In the citing paper
“Therefore, hypoxia can exert a selective pressure that leads to expansion of tumor cells with reduced apoptotic capacity due to, for example, TP53 mutations (Graeber et al., 1996).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Graeber et al., 1996
In the citing paper
“Hypoxia and/or HIFs can mediate chemotherapy resistance through additional mechanisms including: a) hypoxia-induced decreases in tumor cell proliferation (Tannock, 1968); b) metabolic reprogramming; c) hypoxia-driven selection of p53-mutated tumor cells with less apoptotic capacity (Graeber et al., 1996); and d) inhibition of DNA damage (Sullivan & Graham, 2009).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Graeber et al., 1996
Citations
Cites
Apoptosis in the Pathogenesis and Treatment of Disease
Thompson, C. B. (1995) · Science · doi:10.1126/science.7878464 · Cited by 6,524
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
Hockenbery, D., Nuñez, G., Milliman, C., Schreiber, R. D., & Korsmeyer, S. J. (1990) · Nature · doi:10.1038/348334a0 · Cited by 3,720
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
Self-citationDranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Production of high-titer helper-free retroviruses by transient transfection.
Pear, W. S., Nolan, G. P., Scott, M. L., & Baltimore, D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8392 · Cited by 2,266
The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy
Thomlinson, R. H., & Gray, L. H. (1955) · British Journal of Cancer · doi:10.1038/bjc.1955.55 · Cited by 2,219
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
The Molecular Genetics of Cancer
Bishop, J. M. (1987) · Science · doi:10.1126/science.3541204 · Cited by 1,688
Sunburn and p53 in the onset of skin cancer
Ziegler, A., Jonason, A. S., Leffellt, D. J., Simon, J. A., Sharma, H. W., Kimmelman, J., Remington, L., Jacks, T., & Brash, D. E. (1994) · Nature · doi:10.1038/372773a0 · Cited by 1,497
Self-citation
Research works printed but not linked: 9
- Vaupel, P. W. & Hockel, M. in Tumor Oxygenation (eds Vaupel, P. W., Kelleher, D. K. & Gunderoth, M.) 219–232 (Gustav Fischer, Stuttgart, 1995).
- Lord, E. M., Harwell, L. & Koch, C. J. Cancer Res. 53, 5721–5726 (1993).
- Bardeesy, N., Beckwith, J. B. & Pelletier, J. Cancer Res. 55, 215–219 (1995).
- Baker, S. J. et al. Cancer Res. 50, 7717–7722 (1990).
- Sinicrope, F. A. et al. Cancer Res. 55, 237–241 (1995).
- Bedi, A. et al. Cancer Res. 55, 1811–1816 (1995).
- Lotem, J. & Sachs, L. Cell Growth. Differ. 4, 41–47 (1993).
- Lowe, S. W. Curr. Opin. Oncol. (in the press).
- Greenblatt, M. S., Bennett, W. P., Hollstein, M. & Harris, C. C. Cancer Res. 54, 4855–4878 (1994).
Cited by
Items 701–800 of 1,006
Vascular remodeling and clinical resistance to antiangiogenic cancer therapy
GLADEBENDER, J., COONEY, E., KANDEL, J., & Yamashiro, D. J. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2004.09.001 · Cited by 99
Expression of hypoxia‐inducible factor 1α in tumours of patients with glioblastoma
Søndergaard, K. L., Hilton, D. A., Penney, M., Ollerenshaw, M., & Demaine, A. G. (2002) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2002.00391.x · Cited by 87
Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors
Siemann, D. W., & Shi, W. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.08.002 · Cited by 87
Strategien zur Modulation von Protein‐Protein‐Wechselwirkungen mit synthetischen Substanzen
Yin, H. H., & Hamilton, A. D. (2005) · Angewandte Chemie · doi:10.1002/ange.200461786 · Cited by 88
Lyng, H., Sundfør, K., Tropé, C. G., & Rofstad, E. K. (2000) · PubMed · Cited by 87
Role of Hypoxic Stress in Regulating Tumor Immunogenicity, Resistance and Plasticity
Terry, S., Zaarour, R. F., Venkatesh, G. H., Francis, A., El‐Sayed, W., Buart, S., Bravo, P. E., Thiery, J., & Chouaïb, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103044 · Cited by 96
Vitexin, an HIF-1α Inhibitor, Has Anti-metastatic Potential in PC12 Cells
Choi, H. J., Eun, J. S., Kim, B. G., Kim, S. Y., Jeon, H., & Soh, Y. (2006) · Molecules and Cells · doi:10.1016/s1016-8478(23)17423-1 · Cited by 72
Hypoxia in head and neck cancer
Isa, A., Ward, T. H., West, C., Slevin, N. J., & Homer, J. J. (2006) · British Journal of Radiology · doi:10.1259/bjr/17904358 · Cited by 91
“There is evidence that hypoxia enhances genetic instability in tumour cells and selects for tumour cell populations with diminished apoptotic potential, and increased aggressiveness and metastatic potential [17–19].”
BackgroundPiret, J., Lecocq, C., Toffoli, S., Ninane, N., Raes, M. J., & Michiels, C. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.01.024 · Cited by 96
“The evolution of tumoral cells in this hypoxic environment depends on the selection of a cell population which on one hand, is resistant to apoptosis [16] and on the other hand, induces formation of new blood vessels [17–19].”
BackgroundThe role of radiation-induced apoptosis as a determinant of tumor responses to radiation therapy
Rupnow, B. A., & Knox, S. J. (1999) · APOPTOSIS · doi:10.1023/a:1009675028784 · Cited by 98
Genetic basis of tolerance to O 2 deprivation in Drosophila melanogaster
Haddad, G. G., Sun, Y., Wyman, R. J., & Xu, T. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10809 · Cited by 86
Hypoxia Selection of Death-resistant Cells
Dong, Z., & Wang, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312225200 · Cited by 87
UVB-induced apoptosis drives clonal expansion during skin tumor development
Zhang, W. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh300 · Cited by 85
Koumenis, C., & Giaccia, A. J. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.12.7306 · Cited by 86
“Increased expression of the proto-oncogene c-myc increases the apoptotic potential of cells under certain conditions of stress (15, 19 , 22), while the proto-oncogene product bcl-2 has been shown to protect c-Myc-upregulated cells from apoptosis (22).”
BackgroundMethodInfluentialSelf-citationHofer, T., Desbaillets, I., Höpfl, G., Gassmann, M., & Wenger, R. H. (2001) · The FASEB Journal · doi:10.1096/fj.01-0546fje · Cited by 84
“Increased p53 expression under conditions of severe hypoxia is associated with growth arrest and apoptosis (41, 42).”
BackgroundElas, M., Bell, R., Hleihel, D., Barth, E. D., McFaul, C. A., Haney, C. R., Bielańska, J., Pustelny, K., Ahn, K., Pelizzari, C. A., et al. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.02.022 · Cited by 87
Periyasamy, G., Somasundaram, S. T., Perumal, K., Vishwakarma, R. A., Karthikeyan, N. P., Velmurugan, R., & Balakrishnan, A. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600422 · Cited by 85
“It has been shown earlier that c-myc enhances apoptosis in low concentrations of survival factors or oxygen and following treatment with diverse cytotoxic agents (Evan et al, 1992; Graeber et al, 1996).”
BackgroundThe role of hypoxia inducible factor-1alpha in gynecological cancer
Seeber, L. M. S., Horrée, N., Vooijs, M., Heintz, A. P. M., van der Wall, E., Verheijen, R. H. M., & van Diest, P. J. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.05.003 · Cited by 88
“[81] Graeber TG, Osmanian C, Jacks T, et al.”
BackgroundYang, J., Ahmed, A., Poon, E., Perusinghe, N., de Haven Brandon, A., Box, G., Valenti, M., Eccles, S., Rouschop, K., Wouters, B., et al. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00959-08 · Cited by 85
“strong apoptosis (20), while apoptosis is significantly reduced”
BackgroundThe role of ATM and ATR in the cellular response to hypoxia and re-oxygenation
Hammond, E. M., & Giaccia, A. J. (2004) · DNA repair · doi:10.1016/j.dnarep.2004.03.035 · Cited by 93
“Hypoxia is also a physiological inducer of the p53 tumor suppressor gene product and can act as a selective pressure during tumor growth for the elimination of cells with wild-type p53 and the clonal expansion of cells with mutant or otherwise inactive p53 protein [ 10 ,11].”
BackgroundSelf-citationIncreased radiosensitivity with chronic hypoxia in four human tumor cell lines
Zölzer, F., & Streffer, C. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)02963-2 · Cited by 85
Dence, C. S., Ponde, D. E., Welch, M. J., & Lewis, J. S. (2008) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2008.06.001 · Cited by 85
Kaluzová, M., Kaluz, S., Lerman, M. I., & Stanbridge, E. J. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.13.5757-5766.2004 · Cited by 83
Targeting tumor vascularization: promising strategies for vascular normalization
Zheng, R., Li, F., Li, F., & Gong, A. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03701-8 · Cited by 93
Underscoring the Influence of Inorganic Chemistry on Nuclear Imaging with Radiometals
Zeglis, B. M., Houghton, J. L., Evans, M. J., Viola, N. T., & Lewis, J. S. (2013) · Inorganic Chemistry · doi:10.1021/ic401607z · Cited by 97
Metabolic mapping with bioluminescence: basic and clinical relevance
Walenta, S., Schroeder, T., & Mueller‐Klieser, W. (2002) · Biomolecular Engineering · doi:10.1016/s1389-0344(01)00107-1 · Cited by 85
Mitochondrial Regulation of Cell Survival and Death During Low-Oxygen Conditions
Snyder, C. M., & Chandel, N. S. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2730 · Cited by 81
“Anoxia will select for tumor cells that have mutations in p53 or overexpress antiapoptotic BCL-2 proteins, because these on-cogenically transformed cells are resistant to anoxia-induced cell death (31).”
Verras, M., Papandreou, I., Lim, A. L., & Denko, N. C. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00947-08 · Cited by 84
“The net result is a stressful environment that can adversely effect tumor cell proliferation and survival and select for aggressive clonogens (12).”
BackgroundProspective strategies to enforce selectively cell death in cancer cells
Blagosklonny, M. V. (2004) · Oncogene · doi:10.1038/sj.onc.1207520 · Cited by 94
“However, cancer cell can acquire resistance to hypoxia (Graeber et al., 1996), and hence to antiangiogenic therapy (Yu et al., 2002).”
BackgroundDong, D., Dubeau, L., Bading, J. R., Nguyen, K., Luna, M. C., Yu, H., Bornstein, G. G., Gordon, E. M., Gomer, C. J., Hall, F. L., et al. (2004) · Human Gene Therapy · doi:10.1089/104303404323142006 · Cited by 91
Gleich, L. L., Biddinger, P. W., Duperier, F. D., & Gluckman, J. L. (1997) · Head & Neck · doi:10.1002/(sici)1097-0347(199707)19:4<243::aid-hed1>3.0.co;2-0 · Cited by 84
Effect of hypoxia on Ad5 infection, transgene expression and replication
Shen, B. H., & Hermiston, T. W. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302448 · Cited by 86
Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin
Belenkov, S., Shenouda, G., Rizhevskaya, E., Cournoyer, D., Belzile, J.-P., Souhami, L., Dević, S., & Chow, T. Y.-K. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1525.3.12 · Cited by 84
“Moreover, hypoxic neoplastic cells are clinically more aggressive and have a more metastatic potential than their well-oxygenated counterparts (4, 5).”
BackgroundIntegrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy
Abou Khouzam, R., Goutham, H. V., Zaarour, R. F., Chamseddine, A. N., Francis, A., Buart, S., Terry, S., & Chouaib, S. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.003 · Cited by 83
Lee, C.-H., Wu, C.-L., Tai, Y.-S., & Shiau, A.-L. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.01.008 · Cited by 83
“Hypoxia is also associated with a more malignant phenotype, which affects genomic stability, apoptosis, angiogenesis, and metastasis [9].”
BackgroundGrigsby, P. W., Malyapa, R. S., Higashikubo, R., Schwarz, J. K., Welch, M. J., Huettner, P. C., & Dehdashti, F. (2007) · Molecular Imaging and Biology · doi:10.1007/s11307-007-0095-2 · Cited by 83
“Tumor hypoxia contributes to the process of malignant tumor progression by several mechanisms including elimination of p53 tumor suppressor gene activity [2], induction of protooncogene expression [3], and angiogenesis [4].”
BackgroundYamada, D., Kobayashi, S., Yamamoto, H., Tomimaru, Y., Noda, T., Uemura, M., Wada, H., Marubashi, S., Eguchi, H., Tanemura, M., et al. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1797-x · Cited by 90
Montel, V., Gaultier, A., Lester, R. D., Campana, W. M., & Gonias, S. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0683 · Cited by 82
“Unfortunately, these programs may select cancer cells with aggressive phenotypes (25, 26).”
BackgroundTranscriptional repression of human cad gene by hypoxia inducible factor-1
Chen, K.-F. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki839 · Cited by 82
“It has been reported that hypoxia may induce apoptosis in p53 cells (2).”
BackgroundAutocrine production of IL-11 mediates tumorigenicity in hypoxic cancer cells
Onnis, B., Fer, N. D., Rapisarda, A., Perez, V. S., & Melillo, G. (2013) · Journal of Clinical Investigation · doi:10.1172/jci59623 · Cited by 85
“In addition, hypoxia may select for cells resistant to apoptosis (3) and may induce genetic instability (4); however, the mechanism(s) by which hypoxia may contribute to tumorigenicity are still poorly understood.”
Cellular response to tissue hypoxia and its involvement in disease progression
Ikeda, E. (2005) · Pathology International · doi:10.1111/j.1440-1827.2005.01877.x · Cited by 94
Yao, K., Gietema, J. A., Shida, S., Selvakumaran, M., Fonrose, X., Haas, N. B., Testa, J., & O'Dwyer, P. J. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602864 · Cited by 82
“…event is responsible for both increased susceptibility to apoptosis and the altered doubling time, consistent with the previous demonstration that the hypoxic environment facilitates mutational events (Graeber et al, 1996) and plausible especially in a cell line deficient in DNA mismatch repair.”
BackgroundCahlin, C., Gélin, J., Delbro, D. S., Lönnroth, C., Doi, C., & Lundholm, K. (2000) · PubMed · Cited by 82
Coquelle, A., Rozier, L., Dutrillaux, B., & Debatisse, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205880 · Cited by 81
“We previously demonstrated that oxygen privation (hypoxia), an important parameter of the tumor microenvironment (Brizel et al., 1996; Graeber et al., 1996; Kinzler and Vogelstein, 1996), which enhances gene amplification frequency (Luk et al., 1990; Rice et al., 1986), induces breaks at fragile…”
BackgroundColpaert, C., Vermeulen, P., van Beest, P., Goovaerts, G., Weyler, J., van Dam, P., Dirix, L. Y., & Marck, E. V. (2001) · Histopathology · doi:10.1046/j.1365-2559.2001.01238.x · Cited by 88
“Hypoxia mediates the selection of cells with mutant p53 by stimulating apoptosis of cells expressing wild-type p53.(37) Oxygen deprivation increases the gene expression of inducible nitric oxide (NO) synthase.”
BackgroundSalnikow, K., Costa, M., Figg, W. D., & Blagosklonny, M. V. (2000) · PubMed · Cited by 91
Apoptosis and gastrointestinal pharmacology
Pritchard, D. M., & Watson, A. J. M. (1996) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(96)00102-7 · Cited by 90
Raju, U., Gumin, G. J., & Tofilon, P. J. (1999) · Radiation Oncology Investigations · doi:10.1002/(sici)1520-6823(1999)7:3<145::aid-roi2>3.0.co;2-r · Cited by 38
Raitila, A., Lehtonen, H. J., Arola, J. T., Heliövaara, E., Ahlsten, M., Georgitsi, M., Jalanko, A., Paetau, A. E., Aaltonen, L. A., & Karhu, A. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.100138 · Cited by 81
Kennedy, A. S., Harrison, G. H., Mansfield, C. M., Zhou, X. J., Xu, J., & Balcer‐Kubiczek, E. K. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000820)90:4<199::aid-ijc3>3.0.co;2-c · Cited by 29
Prevention of motoneuron death by adenovirus-mediated neurotrophic factors
Gim�nez y Ribotta, M., Revah, F., Pradier, L., Loquet, I., Mallet, J., & Privat, A. (1997) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19970501)48:3<281::aid-jnr11>3.0.co;2-4 · Cited by 104
Kleinberg, L. R., Grossman, S. A., Carson, K. A., Lesser, G. J., O’Neill, A., Pearlman, J. L., Phillips∥, P. C., Herman, T., & Gerber, M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.01.096 · Cited by 81
p53 inhibits entry into mitosis when DNA synthesis is blocked
Taylor, W. R., Agarwal, M. L., Agarwal, A. M., Stacey, D. W., & Stark, G. R. (1999) · Oncogene · doi:10.1038/sj.onc.1202516 · Cited by 88
“…al., 1993; Dulic et al., 1994; Miyashita and Reed, 1995; Attardi et al., 1996; Agarwal et al., 1997). p53 is also activated in response to stimuli that do not generate broken DNA directly, including nucleotide deprivation and hypoxia (Linke et al., 1996; Graeber et al., 1996; Agarwal et al., 1997).”
BackgroundIdentification of Genes Differentially Induced by Hypoxia in Pancreatic Cancer Cells
Yoon, D. Y., Büchler, P., Saarikoski, S. T., Hines, O. J., Reber, H. A., & Hankinson, O. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5867 · Cited by 81
Metabolism and Its Sequelae in Cancer Evolution and Therapy
Gillies, R. J., & Gatenby, R. A. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000102 · Cited by 85
“For example, hypoxia has been shown by Graber and others to select for p53 deficiency presumably to increase survival in the harsh physical microenvironment.(18)We have observed spontaneous loss of p53 via chromosomal deletions in 2 different breast epithelial cell lines flowing selection by intermittent hypoxia.”
BackgroundChen, X., Litzenburger, U. M., Wei, Y., Schep, A. N., LaGory, E. L., Choudhry, H., Giaccia, A. J., Greenleaf, W. J., & Chang, H. Y. (2018) · Nature Communications · doi:10.1038/s41467-018-07115-y · Cited by 80
Self-citationKhouzam, R. A., Zaarour, R. F., Brodaczewska, K. K., Azakir, B., Venkatesh, G. H., Thiery, J., Terry, S., & Chouaïb, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.828875 · Cited by 83
The transcription factor Egr1 regulates the HIF‐1α gene during hypoxia
Sperandio, S., Fortin, J., Šášik, R., Robitaille, L., Corbeil, J., & de Belle, I. (2008) · Molecular Carcinogenesis · doi:10.1002/mc.20454 · Cited by 95
“an accurate prognostic indicator [3,4], and tumor hypoxic adaptation is considered a major cause of treatment failure [5,6].”
BackgroundRegulation of cancer metastasis by stress pathways
Xie, K., & Huang, S. (2003) · Clinical & Experimental Metastasis · doi:10.1023/a:1022590402748 · Cited by 87
“is similar to that provided by hypoxia [146, 147].”
ResultBellamy, C. O. C. (1997) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a011628 · Cited by 80
Yatsugi, N., Tsukazaki, T., Osaki, M., Koji, T., Yamashita, S., & Shindo, H. (2000) · Journal of Orthopaedic Science · doi:10.1007/s007760050142 · Cited by 80
Therapeutic targets in radiotherapy
Brown, J. M. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)01482-6 · Cited by 80
“This is because hypoxia may select for a more malignant phenotype ( 38 ) and has been associated clinically with increased metastatic frequency (37, 39, 40).”
BackgroundRecent Developments in the Molecular Characterization of Barrett’s Esophagus
Fitzgerald, R. C., & Triadafilopoulos, G. (1998) · Digestive Diseases · doi:10.1159/000016850 · Cited by 83
The growing complexity of HIF-1α’s role in tumorigenesis: DNA repair and beyond
Rohwer, N., Zasada, C., Kempa, S., & Cramer, T. (2012) · Oncogene · doi:10.1038/onc.2012.510 · Cited by 88
Ren, Y. X., Hao, P., Dutta, B., Cheow, E. S. H., Sim, K. H., Gan, C. S., Lim, S. K., & Sze, S. K. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.018325 · Cited by 79
JELKMANN, W. E. B., & Hellwig‐Bürgel, T. (2001) · Advances in experimental medicine and biology · doi:10.1007/978-1-4757-3401-0_12 · Cited by 92
Promotion of glioma cell survival by acyl-CoA synthetase 5 under extracellular acidosis conditions
Mashima, T., Sato, S., Sugimoto, Y., TSURUO, T., & Seimiya, H. (2008) · Oncogene · doi:10.1038/onc.2008.355 · Cited by 84
Engineering bacteria toward tumor targeting for cancer treatment: current state and perspectives
Lee, C. (2011) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-011-3695-3 · Cited by 79
Intermittent Hypoxia Regulates Stem-like Characteristics and Differentiation of Neuroblastoma Cells
Bhaskara, V. K., Mohanam, I., Rao, J. S., & Mohanam, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030905 · Cited by 79
Ameri, K., Hammond, E. M., Culmsee, C., Raida, M., Katschinski, D. M., Wenger, R. H., Wagner, E., Davis, R. J., Hai, T., Denko, N. C., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209781 · Cited by 84
“Tumor hypoxia/anoxia is associated with a more aggressive clinical phenotype (Graeber et al., 1996; Le et al., 2004).”
BackgroundBryce, N. S., Zhang, J. Z., Whan, R. M., Yamamoto, N., & Hambley, T. W. (2009) · Chemical Communications · doi:10.1039/b902415h · Cited by 78
Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302
Wojtkowiak, J. W., Cornnell, H. C., Matsumoto, S., Saito, K., Takakusagi, Y., Dutta, P., Kim, M., Zhang, X., Leos, R. A., Bailey, K. M., et al. (2015) · Cancer & Metabolism · doi:10.1186/s40170-014-0026-z · Cited by 79
“Finally, chronic hypoxia has been shown to select for cells that are resistant to apoptosis [32,33].”
Backgroundp53 in Tumor Progression: Life, Death, and Everything
Mowat, M. R. A. (1998) · Advances in cancer research · doi:10.1016/s0065-230x(08)60764-2 · Cited by 85
RNA‐binding protein Csx1 mediates global control of gene expression in response to oxidative stress
Rodríguez‐Gabriel, M. A., Burns, G., McDonald, W. H., Martín, V., Yates, J. R., Bähler, J., & Russell, P. R. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg597 · Cited by 90
Loktionov, A. S., O'Neill, I. K., Silvester, K. R., Cummings, J. H., Middleton, S. J., & Miller, R. N. (1998) · PubMed · Cited by 78
van Slooten, H.-J., van de Vijver, M. J., van de Velde, C., & van Dierendonck, J. H. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.128 · Cited by 78
Up-regulation of hypoxia-inducible factor-1alpha is not sufficient for hypoxic/anoxic p53 induction.
Wenger, R. H., Camenisch, G., Desbaillets, I., Chilov, D., & Gassmann, M. (1998) · PubMed · Cited by 97
Cellular reaction to hypoxia: sensing and responding to an adverse environment
Papandreou, I., Powell, A. A., Lim, A. L., & Denko, N. C. (2004) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2004.06.054 · Cited by 90
Hypoxia Markers in Human Osteosarcoma: An Exploratory Study
Mizobuchi, H., García-Castellano, J. M., Philip, S., Healey, J. H., & Gorlick, R. G. (2008) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-008-0328-y · Cited by 82
Tumor Hypoxia, Dna Repair and Prostate Cancer Progression: New Targets and New Therapies
Chan, N. H. L., Milosevic, M., & Bristow, R. G. (2007) · Future Oncology · doi:10.2217/14796694.3.3.329 · Cited by 87
“Using defined genetic models, Graebner and colleagues first observed that hypoxia could select for mutant p53expressing cells that had reduced stress-induced apoptosis and an increased cell-survival advantage when compared with wild-type p53expressing cells [45].”
BackgroundGeng, H., Xue, C., Mendonca, J., Sun, X., Liu, Q., Reardon, P. N., Chen, Y., Qian, K., Hua, V. J., Chen, A. P., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07411-7 · Cited by 82
Bouck, N. (1996) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(96)00005-4 · Cited by 77
Barr, M. P., Bouchier-Hayes, D., & Harmey, J. H. (2008) · International Journal of Oncology · doi:10.3892/ijo.32.1.41 · Cited by 81
“This hypoxic stress also exerts a selective pressure within tumours, supporting the expansion of cells with reduced apoptotic potential (27).”
BackgroundHypoxia–Induced Cytotoxic Drug Resistance in Osteosarcoma Is Independent of HIF-1Alpha
Adamski, J., Price, A., Dive, C., & Makin, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065304 · Cited by 81
“[47] In p53 wild type cells, suppression of p53 activity protects against cytotoxic-induced apoptosis.”
BackgroundTumor Microenvironment and Metabolism in Prostate Cancer
Chiarugi, P., Paoli, P., & Cirri, P. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.03.004 · Cited by 82
Angiogenesis: A Target for Cancer Therapy
Tortora, G., Melisi, D., & Ciardiello, F. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043453595 · Cited by 76
Jensen, P. Ø., Mortensen, B. T., Hodgkiss, R. J., Iversen, P. O., Christensen, I. J., Helledie, N., & Larsen, J. K. (2000) · Cell Proliferation · doi:10.1046/j.1365-2184.2000.00183.x · Cited by 76
Oncogenes and tumor angiogenesis
Rak, J. W., & Yu, J. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2003.09.014 · Cited by 90
Park, S., Billiar, T. R., & Seol, D. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6421 · Cited by 76
Nakanishi, K., Hiroi, S., Tominaga, S. O., Aida, S., Kasamatsu, H., Matsuyama, S., 松山, 智., & Kawai, T. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1685 · Cited by 84
Hypoxia in the tumorigenesis of gliomas and as a potential target for therapeutic measures
Jensen, R. L. (2006) · Neurosurgical Focus · doi:10.3171/foc.2006.20.4.16 · Cited by 76
Modulation of cell death in the tumor microenvironment.
Wouters, B., Koritzinsky, M., Chiu, R. K., Theys, J., Buijsen, J., & Lambin, P. (2003) · Seminars in Radiation Oncology · doi:10.1053/srao.2003.50004 · Cited by 79
Ács, G., Chen, M., Xu, X., Acs, P. I., Verma, A. M., & Koch, C. J. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.04.027 · Cited by 76
“solid tumors [1,2].”
BackgroundSelf-citationHypoxia and Oxygen-Sensing Signaling in Gene Regulation and Cancer Progression
Yang, G., Shi, R., & Zhang, Q. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218162 · Cited by 80
Büchler, P., Reber, H. A., Tomlinson, J. S., Hankinson, O., Kallifatidis, G., Friess, H., Herr, I., & Hines, O. J. (2009) · Neoplasia · doi:10.1593/neo.08734 · Cited by 73
“It has been suggested that hypoxia selects for more malignant cell clones, that is, by promoting those with diminished apoptotic potential owing to p53 alterations [ 8 ] or, for example, by activating adenosine A(3) receptor–Akt pathway, which mediates Bad inactivation and favors cell survival [9,10].”
BackgroundVerduzco, D., Lloyd, M., Xu, L., Ibrahim-Hashim, A., Balagurunathan, Y., Gatenby, R. A., & Gillies, R. J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0120958 · Cited by 75
“In vitro studies have shown that hypoxia selects for cells carrying mutations in p53 such that minor populations engineered to carry nonfunctional alleles of TP53 eventually overtake populations wild-type for TP53 [11], which can lead to apoptosis resistance.”
BackgroundQuesada, A. J., Nelius, T., Yap, R. X. J., Zaichuk, T. A., Alfranca, A., Filleur, S., Volpert, O. V., & Redondo, J. M. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401615 · Cited by 78
Targeting the molecular basis for tumour hypoxia
Carroll, V. A., & Ashcroft, M. A. (2005) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399405009117 · Cited by 108
Yang, Q., Zeng, B., Dong, Y., Shi, Z., Jiang, Z.-M., & Huang, J. (2007) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyl137 · Cited by 78
“There is also evidence that hypoxia may be responsible for a variety of growthmodulating effects that could confer a growth advantage upon the malignant cells (8,9).”
BackgroundThe use of clostridial spores for cancer treatment
Barbé, S., Mellaert, L. V., & Anné, J. (2006) · Journal of Applied Microbiology · doi:10.1111/j.1365-2672.2006.02886.x · Cited by 75
“In addition, hypoxia in tumours tends to select for a more malignant phenotype (Graeber et al. 1996), increases expression of genes associated with angiogenesis (Harris 2002) and is associated with a more metastatic phenotype of human cancers (Subarsky and Hill 2003).”
Metadata
- Authors
- Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J.
- Affiliations
- Stanford Medicine (US)
- Howard Hughes Medical Institute (US)
- Massachusetts Institute of Technology (US)
- University of Pennsylvania (US)
- Cold Spring Harbor Laboratory (US)
- Venue
- Nature
- Published
- 1996-01
- Volume
- 379
- Issue
- 6560
- Pages
- 88-91
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2028999918
- Cited by
- 2,300
- References
- 31
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 16 · 2023: 30 · 2022: 27 · 2021: 55 · 2020: 39 · 2019: 37 · 2018: 37 · 2017: 51 · 2016: 56 · 2015: 56 · 2014: 41 · 2013: 70 · 2012: 78
- FWCI
- 52.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- tumor hypoxia, apoptosis, solid tumors, p53, Bcl-2, p53 deficiency, tumor necrosis, tumor heterogeneity, tumor suppressor
- MeSH terms
- Animals, Cell Line, Transformed, Cell Transformation, Neoplastic, Neoplasm Transplantation, Neoplasms, Oxygen, Proto-Oncogene Proteins, Receptors, Estrogen, Tamoxifen, Cell Hypoxia, Genes, p53, Proto-Oncogene Proteins c-myc, Apoptosis, Proto-Oncogene Proteins c-bcl-2, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.